Rachel Carlson

David Olson is one of these researchers. He's a chemical neuroscientist at UC Davis, and he says neuropsychiatric disease is a huge problem globally. We're talking in the neighborhood of a billion people.

So, Gina, let's go back to our big question here. Why might drugs like psychedelics or ketamine help people? Is it because of the way they could alter the brain or the trip or experience that comes with them? Yeah. David's saying forget the trip. He's betting on their chemical and biological effect.

So, Gina, let's go back to our big question here. Why might drugs like psychedelics or ketamine help people? Is it because of the way they could alter the brain or the trip or experience that comes with them? Yeah. David's saying forget the trip. He's betting on their chemical and biological effect.

So, Gina, let's go back to our big question here. Why might drugs like psychedelics or ketamine help people? Is it because of the way they could alter the brain or the trip or experience that comes with them? Yeah. David's saying forget the trip. He's betting on their chemical and biological effect.

A lot of his research is focused on creating new psychedelics and even drugs that are inspired by psychedelics, but he says could be more accessible and safer since lots of people can't take psychedelics. Right. And researchers still don't really know the long-term effects of taking these drugs.

A lot of his research is focused on creating new psychedelics and even drugs that are inspired by psychedelics, but he says could be more accessible and safer since lots of people can't take psychedelics. Right. And researchers still don't really know the long-term effects of taking these drugs.

A lot of his research is focused on creating new psychedelics and even drugs that are inspired by psychedelics, but he says could be more accessible and safer since lots of people can't take psychedelics. Right. And researchers still don't really know the long-term effects of taking these drugs.

That's one aspect of his work. So we'll get into this process tomorrow on Shortwave.

That's one aspect of his work. So we'll get into this process tomorrow on Shortwave.

That's one aspect of his work. So we'll get into this process tomorrow on Shortwave.

Thanks, Gina. I produced this episode with Burley McCoy. It was edited by our showrunner Rebecca Ramirez and Jeff Brumfield. Tyler Jones checked the facts. Kwesi Lee was the audio engineer. Special thanks to John Hamilton, Brent Bachman, Johanna Sturgey, and our incredible standards team.

Thanks, Gina. I produced this episode with Burley McCoy. It was edited by our showrunner Rebecca Ramirez and Jeff Brumfield. Tyler Jones checked the facts. Kwesi Lee was the audio engineer. Special thanks to John Hamilton, Brent Bachman, Johanna Sturgey, and our incredible standards team.

Thanks, Gina. I produced this episode with Burley McCoy. It was edited by our showrunner Rebecca Ramirez and Jeff Brumfield. Tyler Jones checked the facts. Kwesi Lee was the audio engineer. Special thanks to John Hamilton, Brent Bachman, Johanna Sturgey, and our incredible standards team.

Hey, Gina. So psychedelics are being studied to treat lots of different kinds of conditions.

Hey, Gina. So psychedelics are being studied to treat lots of different kinds of conditions.

Hey, Gina. So psychedelics are being studied to treat lots of different kinds of conditions.

That's Albert Garcia-Romeo. He's a psychologist and psychopharmacologist at Johns Hopkins University. Albert ran a study using a psychedelic called psilocybin. It's the active ingredient in magic mushrooms. And he wanted to see if it could help people who'd previously had Lyme disease.

That's Albert Garcia-Romeo. He's a psychologist and psychopharmacologist at Johns Hopkins University. Albert ran a study using a psychedelic called psilocybin. It's the active ingredient in magic mushrooms. And he wanted to see if it could help people who'd previously had Lyme disease.

That's Albert Garcia-Romeo. He's a psychologist and psychopharmacologist at Johns Hopkins University. Albert ran a study using a psychedelic called psilocybin. It's the active ingredient in magic mushrooms. And he wanted to see if it could help people who'd previously had Lyme disease.

Because you may not realize it, but Lyme disease often comes with lots of psychological symptoms in addition to all the physical ones. Lori Unruh Snyder is one of Albert's patients in that study. She's an agriculture professor. She got a tick bite. She got Lyme disease. But it took doctors four years to get to that diagnosis.